Objective. Patients with RA have an increased risk of cardiovascular disease. Management of RA has changed substantially over time. Our aim was to evaluate changes in cardiovascular morbidity and mortality over the period of 1978-2002. Methods. Two cohorts of consecutive patients with RA seen at outpatient clinics in Malmö , Sweden, were started in 1978 (n ¼ 148) and 1995 (n ¼ 161) and compared with the corresponding background population. Patients were followed for 8 years, and fatal and non-fatal cardiovascular first events were identified using two national registers, hospital discharge and cause of death. Standardized morbidity ratio (SMoR) and standardized mortality ratio (SMR), adjusted for age and sex were calculated. Results. Sex distribution, age at disease onset and disease duration were similar in both groups. The 1995 cohort was more extensively treated with DMARDs and had less disease activity and disability. Total cardiovascular morbidity was increased in the 1978 cohort (SMoR 158; 95% CI 111, 225) as well as in the 1995 cohort (SMoR 168; 95% CI 118, 232). This was mainly due to an increased risk of coronary artery disease. Overall mortality was elevated in the 1978 cohort but not in the 1995 cohort. There was no change in cardiovascular excess mortality (SMR 175; 95% CI 100, 284; and 172; 100, 276 for the two cohorts, respectively).
Introduction
RA is a chronic systemic inflammatory disease that leads to joint destruction and has a major effect on quality of life. RA-related chronic inflammation not only affects the joints but also the vascular system, which contributes to the increased comorbidity and premature mortality compared with the general population, especially from coronary artery disease (CAD) [1] [2] [3] [4] .
There is some evidence for secular changes in the incidence and severity of RA. Prevalence estimates have varied between 0.5 and 1.0% in the Caucasian population, but recent studies from Scandinavia suggest that the prevalence is close to 0.5% in the adult population [5, 6] . A decreasing incidence over time as well as a shift towards older age at RA onset has been reported [7] [8] [9] [10] .
The treatment of RA has changed substantially over the last three decades, with earlier and more extensive use of DMARDs, and during the last decade introduction of TNF inhibitors and other biologic agents [11] . We have previously reported data indicating a reduced disease activity and disability in patients with RA [12] , and other studies corroborate these findings [13, 14] . A corresponding decrease in the risk of comorbidity and premature mortality over time might be expected, and this concept has been supported by observational studies of patients with RA treated with MTX [15, 16] . However, in a long-term populationbased study, there was no change in RA-associated excess mortality over several decades [17, 18] .
The main aim of this article was to estimate the relative risk for cardiovascular comorbidity and mortality in two cohorts of patients with RA initiated in 1978 and 1995 [12, 19] compared with the background population, and to investigate changes over time in RA-associated comorbidity. We also evaluated traditional risk factors for cardiovascular disease (CVD), as well as disease severity markers, and studied their effect on the cardiovascular burden in these patients.
Methods

Patients in the 1978 and 1995 cohorts
The cohort from 1978 consisted of 148 consecutive patients who fulfilled the 1958 American Rheumatism Association (ARA) criteria for RA [20] , and were seen during 1 month at the outpatient rheumatology clinic at Malmo¨University Hospital [19] . This is the only hospital serving the population of Malmo¨(237 000 inhabitants in 1978 and 246 000 inhabitants in 1995). In 1978, this was the only outpatient clinic for rheumatology in the city.
The patient cohort from 1995 consisted of 161 consecutive patients (10 patients were included in both cohorts) who fulfilled the 1987 ARA criteria for RA [21] and who, during 1 month, visited either the outpatient rheumatology clinic at MalmoÜ niversity Hospital or the outpatient clinics of two board-certified rheumatologists working outside the hospital. Previous surveys indicate that >90% of all patients with RA in the city were seen at these clinics [22, 23] .
All patients were systematically evaluated at baseline, using a structured protocol, including joint tenderness, disability, CRP and RF analysis as part of a previous study [12] , evaluating differences in disease severity and treatment between 1978 and 1995.
Disease activity was clinically evaluated using Ritchie's articular index, which is a score for joint tenderness based on the examination of 53 joints with scoring of 26 joint areas (score range 0-78) [24] . Functional disability was evaluated according to the Steinbrocker functional class index, which categorizes the patients into four classes based on the patient's ability to perform everyday activities [25] .
The serum levels of CRP were analysed by the routine method at the Department of Clinical Chemistry, Malmo¨University Hospital, which had the same reference values for normal/ abnormal values in both periods. RF was analysed at the Department of Microbiology using the bentonite flocculation test (BFT) and the SCAT on both occasions [26] . In this study, the patients were considered as RF seropositive when they had a SCAT titre of 51/16 or BFT 51/40. In both patient groups, information on present and previous treatment with DMARDs and glucocorticosteroids was obtained through a structured review of all the clinical records.
Through a second structured review in 2007 of both cohorts, we registered information on diabetes (diagnosed before inclusion or on treatment at inclusion), blood pressure (at inclusion or 1 year before or after inclusion, registered in subsequent case records) and current pharmacological treatment focusing on heart and anti-hypertensive agents, anti-thrombotic drugs and on NSAIDs at inclusion. For definition of hypertension diagnosis see Table 2 . The process of data extraction and availability of these data were similar for both cohorts.
Smoking habits (mentioned at inclusion, in case records after inclusion indicating that they smoked at inclusion or mentioned in the case records 41 year before inclusion) and lipid levels (for detailed data availability, see 'Results' section) were also registered. For most patients, data on smoking and lipid levels were not available at inclusion, but could be extracted from other visits. At the time of this review, five medical records (two in the 1978 cohort and three in the 1995 cohort) could not be obtained.
Standard population and cardiovascular event definition
The general population of Malmo¨, aged 516 years, served as the standard population. The Swedish population register [27] was used to obtain the number of residents in Malmo¨during the study periods.
Data on cardiovascular events were retrieved from the Swedish National Hospital Discharge Register and the Causes of Death Register [27] . The underlying assumption is that, virtually, all clinical significant CAD, cerebrovascular disease (CEVD) or peripheral artery disease (PAD) events would lead to either hospitalization or death. These registers are both administered by the Swedish National Board of Health and Welfare. The hospital discharge register is based on reports from local registers, and includes information on age, sex and place of residence for each individual, as well as the time for hospitalization and discharge diagnoses (primary and secondary), classified according to the International Classification of Diseases, 8th, 9th and 10th revision (ICD-8, -9 and -10) [28] [29] [30] for each inpatient episode. ICD-9 uses the same codes as ICD-8 for diagnoses used in these analyses. The proportion of hospital discharges not reported to the register has been estimated to be 1-2% [27] . In evaluations of the accuracy of registered diagnoses conducted in 1987 and 1995, 86% of the episodes classified as being due to acute myocardial infarction (AMI) fulfilled predefined criteria for definite AMI, whereas 9% was considered to have had possible AMI [27] . The Causes of Death Register is based on compulsory reporting of underlying and contributing causes of death, and contains information on age, sex, place of residence and date of death. In 1996, the register was estimated to include data on 99.64% of all deaths [27] . Previous validation studies of death certification for myocardial infarction have reported confirmation rates of 92-96% [31] .
For both cohorts, data on all hospital episodes with a registered diagnosis (both underlying and contributing causes) of CAD (ICD-10: I21-I25; ICD-9: 410-414), CEVD (ICD-10: I61-I69; ICD-9: 431-438) or PAD (ICD-10: I70-I72, I73.9 and I74; ICD-9: 440-442, 443Â and 444), and all deaths using the same ICD codes were retrieved from the Hospital Discharge Register and Causes of Death Register. For the period 1 January 1974 to 1 January 1997 (for the causes of Death Register) and 1 January 1998 (Hospital Discharge Register) ICD-8 and -9 codes were used; and for the period after these dates to the end of the study, the corresponding ICD-10 codes were used. To get an estimation of prevalent CVD, events for a period of 4 years before baseline, i.e. 1974-78 and 1991-95, were captured in a similar fashion through linkage with the Hospital Discharge Register. The period of 4 years before baseline was used, since the starting date for the Hospital Discharge Register in Malmo¨was 1 January 1974. Patients with prevalent CVD were excluded from the analysis of first-ever CVD events.
Statistical analyses
The groups were compared using the Student's t-test for normally distributed variables, the Mann-Whitney U-test for variables without a normal distribution and the chi-square test for categorical variables. Cardiovascular event rates were calculated for the time periods 1978-85 for the 1978 cohort and 1995-2002 for the 1995 cohort. To enable age-and sex-specific cardiovascular event rates, the male and female subgroup of patients and controls were stratified into 15 age groups (i.e. fourteen 5-year periods: e.g. 15-to 19-year olds, 20-to 24-year olds, etc.; and one 585-year-old group). We also stratified the events into time intervals of 4 years for the 1978 cohort (1978-81 and 1982-85) and the 1995 cohort (1995-98 and 1999-2002) . Based on indirect standardization to the Malmo¨general population, the expected number of events, based on information from the same national registers, i.e. Hospital Discharge Register and the Causes of Death Register, for each group in the RA cohorts was estimated. Age-adjusted standardized mortality rates (SMRs) and standardized morbidity rates (SMoRs) with 95% CIs were calculated for each sex separately for CAD, CEVD and PAD and also for CVD overall. Both fatal and non-fatal events were included in SmoR. In these analyses, a single patient can contribute to all three subgroups (CAD, CEVD and PAD), if the patient has been discharged (or died) with several diagnoses during the follow-up period.
In each of the RA cohorts, the impact of disease severity markers and traditional CVD risk factors on the risk of new-onset cardiovascular morbidity, during the study period, was examined separately using Cox regression, adjusted for age at baseline and sex. The study was approved by the ethics committee at the Medical Faculty at Lund University, Sweden.
Results
Baseline characteristics for the two cohorts
The sex distribution, age at disease onset and disease duration were similar in the two cohorts (Table 1) . Lower disease activity was found in the 1995 cohort, measured by CRP (P < 0.001) and Ritchie's articular index for joint tenderness (P < 0.001). Functional disability classified by Steinbrocker functional class index showed a pattern with twice as many patients in Class I and only half as many in Classes III and IV in the 1995 cohort compared with the 1978 cohort. In the 1978 cohort, a higher proportion was RF-positive cases compared with the 1995 cohort.
Patients in the 1995 cohort were found to take DMARDs and glucocorticosteroids more frequently at baseline, whereas NSAID use did not differ significantly (Table 1) . Patients in the 1995 group had, on average, taken almost twice as many DMARDs during the course of their disease. Combination therapies were not used in any patient in the 1978 cohort and in only one patient in the 1995 cohort.
Occurrence and treatment of traditional risk factors for CVD
In both cohorts, $25% of the patients were treated for hypertension. Blood pressure measured at inclusion was slightly lower in the 1995 cohort (Table 2) . Overall, the proportion treated for hypertension was similar in the two groups, although angiotensive-converting enzyme inhibitors (n ¼ 3) and calcium blockers (n ¼ 10) were only used in 1995, due to lack of availability of these drugs in 1978. Lipid-lowering drugs were not used at all in either of the cohorts. Anti-platelet drugs were used by only nine patients in the 1995 cohort, and none by any in the 1978 cohort. A major proportion of the patients in both cohorts used NSAIDs ( 
Cardiovascular morbidity
Sixty-eight patients had a first-ever cardiovascular event during the study period (31 in the 1978 cohort and 37 in the 1995 cohort). In the 1978 cohort, 24 first-ever events of CAD, 6 of CEVD and 8 of PAD occurred; whereas in the 1995 cohort, the corresponding figures were 23 for CAD, 15 for CEVD and 7 for PAD. Overall CVD morbidity was elevated compared with the background population in the 1978 cohort (SMoR 158; 95% CI 111, 225) as well as in the 1995 cohort (SMoR 173; 95% CI 117, 228). This was mainly due to a significantly increased risk of CAD in both RA cohorts. Hospitalization due to PAD occurred more frequently than expected in both cohorts, although fewer events resulted in less precise estimates for PAD compared with CAD ( Fig. 1) .
Stratification by sex revealed a significantly increased morbidity from CVD overall and CAD in women with RA compared with the general population ( Table 3 ). The estimated SMoRs were slightly higher in the 1995 cohort than in the 1978 cohort, suggesting that RA-associated excess CVD morbidity did not decrease over time in women (Table 3 ). Statistical power is limited for the male subset, as indicated by the wide CIs.
Predictors for CVD events
Substantial RA-related disability (Steinbrocker's functional classes III and IV) was associated with an increased age-and sex-adjusted risk of CVD in the 1995 cohort, as well as in the 1978 cohort (Table 4) . A high baseline CRP (550 mg/l) level also tended to predict CVD in both cohorts, although the association did not reach statistical significance. Hypertension at inclusion was a predictor for CVD events, in particular in the 1995 cohort (Table 4) . Values are given as mean (S.D.) unless otherwise indicated. Hypertension was defined as blood pressure over 140/80 at inclusion, treatment with anti-hypertensive agents or diagnosispredating inclusion. Diabetes was defined as a documented clinical diagnosis at the time of assessment. *P ¼ 0.001 vs the 1995 cohort. **Based on 98 subjects in the 1978 and 62 subjects in the 1995 cohorts, respectively. Values are given as mean (S.D.) unless otherwise indicated. *P ¼ 0.03; **P ¼ 0.001; ***P < 0.001 vs 1995 cohort; 
Mortality
Excess CVD mortality over time was similar in the two cohorts (SMR 175; 95% CI 100, 284 and 172; 95% CI 100, 276 for the 1978 and 1995 cohorts, respectively) ( Table 5 ). On the other hand, the overall mortality during the 8-year follow-up period was significantly increased in the 1978 cohort, but not in the 1995 cohort (Table 5) . However, the 95% CIs overlap, indicating that the difference in mortality between the cohorts was not significant. This difference was mainly due to a lower number of deaths attributed to other causes than CVD. In the 1978 cohort, there were 20 deaths due to other causes (2 malignances, 3 infections, 5 arthritis and 10 miscellaneous) compared with 13.2 expected. In the 1995 cohort, there were 17 deaths due to other causes (three malignances, three infections, six arthritis and five miscellaneous) compared with 19.8 expected.
Discussion
In the present study, we found a significantly increased cardiovascular morbidity and mortality in patients with RA recruited in 1978 as well as in 1995. The pattern was similar in both cohorts in spite of more intensive treatment and more favourable markers of inflammation and disability in the 1995 cohort. Substantial RA-related disability (Steinbrocker's functional classes III and IV) was associated with an increased age-and sex-adjusted risk of CVD in both cohorts, whereas hypertension was a significant predictor in especially the 1995 cohort.
In other recent studies, there is conflicting evidence on mortality due to CVD among patients with RA. In a study of the ARAMIS cohort, a decline in mortality due to myocardial infarction over time (1980-97) was observed [32] , suggesting that improved management may protect patients with RA from cardiovascular death. In contrast, in a recently published survey of patients from a British early RA cohort starting in 1986 with a follow-up of 18 years, deaths from CVD were more frequent than expected, especially from CAD [33] . Estimates of excess and CVD mortalities vary for both early and established RA [34] . The different study designs (inception early arthritis cohorts, prospective or cross-sectional RA studies and clinic-or population-based cohorts) and variations in sample sizes, follow-up and geographic areas may explain some of these discrepancies.
It has been suggested that RA is becoming a milder disease [35] [36] [37] [38] and that the incidence is declining [7, 10, 38, 39] . The particular trends in incidence and severity are, however, difficult to disentangle, since the ACR criteria for RA contain several elements, which reflect disease severity such as the presence of RF and radiological erosions. Furthermore, such temporal trends may be secondary to an earlier and more intensive treatment [40] with DMARDs or flawed by methodological problems [12] .
Possible explanations for less severe disease in the 1995 cohort include selection bias due to better access to rheumatologists and a more effective pharmacological therapy. In the 1995 cohort, compared with 1978, considerably more patients were treated with DMARDs and corticosteroids, the use of MTX had increased and the use of anti-malarials had decreased. In fact, the number of DMARDs ever taken had almost doubled. Despite this increase, only 20% were on MTX and none was on TNF inhibitor therapy at baseline in the 1995 cohort. This is considerably less compared with more recent surveys of the RA population from this catchment area, in which >50% were on MTX therapy and 20% were on anti-TNF therapy in 2005 [11, 41] . Observational studies suggest that DMARD treatment may reduce the excess cardiovascular burden in RA patients. Antimalarials appear to have a favourable effect on lipids and antithrombotic effects [42] , and MTX treatment has been associated with reduced CVD mortality [16] in a large observational study.
Furthermore, recent reports from this geographical area [43] and England [44] demonstrate that anti-TNF treatment reduces CVD comorbidity. Since TNF inhibitors were introduced in Sweden in 1999 and initially used only in a minority of patients, it is unlikely that anti-TNF treatment had any major impact on the development of CVD in the 1995 cohort.
Disease severity, including disability and markers of inflammation such as CRP and ESR, has been shown to predict CVD in subjects with RA [45] . Patients with severe extra-articular RA manifestations are at an increased risk of developing CAD [46] as well as peripheral vascular disease [47] , indicating that systemic inflammation is a major determinant of vascular comorbidity in RA. These previous observations are supported by our findings of a high CRP and Steinbrocher functional class index as being predictors for CVD events. Since Steinbrocker functional class index probably is a more robust marker of long-term disease severity than a single measure of CRP in most patients, it is not surprising that we found Steinbrocker functional class index to be a stronger risk factor for CVD.
Taken together, despite the fact that disability and CRP levels were lower, and treatment with DMARDs was more active in the 1995 cohort compared with the 1978 cohort, CVD incidence was not reduced in the latter cohort. This may be due to the fact that many patients were still not adequately treated in 1995.
CVD mortality was increased compared with the general population in both cohorts, but overall mortality was only increased in the 1978 cohort. The lack of excess overall mortality in the 1995 cohort may be due to limited power, restricted follow-up time or improved survival from non-CVD morbidity.
In previous surveys, traditional risk factors for vascular disease, such as smoking, hypertension, diabetes and hyperlipidaemia, did not fully account for the increased risk of CVD in subjects with RA [48, 49] . In the present study, there was a trend towards fewer smokers and also higher cholesterol levels in the 1995 cohort. The latter finding could be due to better control of inflammation [50] . In the past few years, the risk of adverse vascular events associated with NSAID treatment, in particular with selective COX-2 inhibitors, has been recognized [51] .
In the present study, NSAID treatment at baseline was common in both cohorts. Given the lack of longitudinal data regarding exposure, we were unable to estimate the impact of NSAID treatment on CVD.
One potential problem in this study is that the patient cohorts recruited may have been selected differently. There were more rheumatologists serving the same population in the latter time period, and this could have increased the likelihood of milder cases being seen by a rheumatologist. Such differences in selection would bias the comparison towards lower disease severity and lower disease-associated excess CVD morbidity in the 1995 RA cohort.
Another possible limitation of this study concerns the validity of cardiovascular events. Validation studies have demonstrated a high level of accuracy for the Hospital Discharge Register and the Cause of Death Register, but misclassification is still likely to occur in some cases. There is, however, no intuitive reason to believe that this should have a different effect in the RA cohorts than in the general population. Random misclassification would only decrease the likelihood of detecting true differences between the groups. Another possible limitation relates to left censorship. It would have been advantageous if the cohorts had been based on incident and not prevalent RA cases. In addition, longitudinal data on disease severity and traditional risk factors would probably have been more informative than results from a single structured examination, and would thus have given more precise estimates for the risk factors evaluated. Furthermore, the available data did not enable us to control for differences in life style factors between the RA cohort and the standard population. Smoking [52] and possibly obesity [53] are associated with RA, and this may account for part of the increase of CVD morbidity in this group, although previous surveys do not indicate that this is the major explanation [48] .
A major strength of this study is the uniform follow-up of welldefined cohorts and comparison groups. The availability of detailed national statistics for the background population is crucial for these comparisons and makes it possible to adjust for temporal trends in the general population. Investigation of firstever CVD events in consecutive patients, followed using national registers, reduces the risk of selection bias and uncertainty on right censorship.
In conclusion, we have demonstrated an increased first-ever incidence of cardiovascular morbidity and mortality in two community-based RA cohorts over time, compared with the general population in the corresponding area. This suggests that RA-associated CVD remained a substantial health problem in the community, at least up to the beginning of the 21st century. Heightened awareness of the risk of cardiovascular disease, as well as adequate preventive strategies, are of major importance in the management of patients with RA.
Rheumatology key messages
Elevation in the incidence of cardiovascular comorbidity in RA patients has been identified two decades apart. More has to be done to improve the handling of cardiovascular comorbidity in RA patients. Disability is a major predictor of cardiovascular events in patients with RA.
